SB0415

Find a 2017 Bill:

2017 Regular Session

 

Entitled:

Public Health - Essential Generic Drugs - Price Gouging - Prohibition

Sponsored by:

President

Status:

In the Senate - Hearing 2/15 at 1:00 p.m.


Synopsis:Prohibiting a manufacturer or wholesale distributor from engaging in price gouging in the sale of an essential generic drug; requiring the Maryland Medical Assistance Program to notify the manufacturer of an essential generic drug and the Attorney General of a specified increase in the price of the essential generic drug under specified circumstances; requiring a manufacturer of an essential generic drug to submit a specified statement to the Attorney General within 20 days after receipt of a specified notice; etc.
Analysis:Fiscal and Policy Note
All Sponsors:The President (By Request - Office of the Attorney General) and Senators Conway, Astle, Benson, Currie, Feldman, Ferguson, Guzzone, Kelley, Lee, Madaleno, Manno, Mathias, McFadden, Muse, Nathan-Pulliam, Peters, Pinsky, Ramirez, Robinson, Rosapepe, Smith, Young, and Zucker
Additional Facts:Cross-filed with: HB0631
Bill File Type: Regular
Effective Date(s): October 1, 2017
Committee(s):
Finance  View Committee Hearing
Broad Subject(s):Public Health
Narrow Subject(s):Attorney General
Circuit Courts
Civil Actions -see also- Small Claims
Consumer Protection -see also- Unfair Trade Practices
Drugs -see also- Controlled Dangerous Sub; Substance Abuse
Health -see also- Mental and Behavioral Health
Industry and Technology
Medical Assistance
Notices
Penalties and Sentences -see also- Death Penalty
Pharmacists and Pharmacies
Prices -see also- Consumer Price Index
Records -see also- Land Records; Vital Records
Statutes:Article - Health - General
(2-801 through 2-803)

How a Bill Becomes Law

Legislative Lingo

Explanation of Floor Motions and Actions


February 17, 2017 9:45 A.M.